Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001214659-22-004087)

Filing Details

Accession Number:
0001214659-22-004087
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-17 17:59:49
Reporting Period:
2022-03-15
Accepted Time:
2022-03-17 17:59:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737287 Allogene Therapeutics Inc. ALLO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1662119 Rafael Amado 210 East Grand Ave
South San Francisco CA 94080		 Evp Of R&D And Cmo No No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-03-15 5,169 $7.71 320,119 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.69 to $7.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. Includes 1360 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program.